Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(17)
•••
Post by PsilocybinAlphaon Nov 16, 2020 7:53am
1020 Views
Post# 31905218

MindMed Provides Updates on Trials, Interim Results Q1 2021

MindMed Provides Updates on Trials, Interim Results Q1 2021
Full news here

Your Brief
 
MindMed provides an update on its Phase 2a Proof of Concept study evaluating microdoses of LSD for the treatment of Adult ADHD
 
The Company has reached an agreement on the study protocol with both the Swiss and Dutch health authorities.
 
MindMed is working with their site coordinators in Switzerland and the Netherlands to progress with a patient recruitment strategy.
 
MindMed has also submitted a pre-INDpackage to the FDA for its Project Lucy, a potential Phase 2b Efficacy Trial evaluating LSD Assisted Therapy in anxiety disorders.
 
Finally, the Company has agreed with the Liechti Lab at University Hospital Basel to conduct interim analysis in Q1 2021 for its Phase 2a clinical trial of LSD assisted therapy for anxiety disorders, which is currently underway.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities